Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab as a First-line Therapy for Patients With Metastatic Colorectal Cancer

NCT04380103 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT04380103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04380103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Irinotecan, Oxaliplatin, Capecitabine (XELOXIRI) and Bevacizumab as a First-line Therapy for Patients With Metastatic Colorectal Cancer
Lead sponsor
Chinese Academy of Medical Sciences
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 26, 2020
Completion date
September 30, 2022
Enrollment
106 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, colorectal cancer, metastatic cancer